Research results suggest a preventive role of statins in the late-onset form of preeclampsia
HENNIGSDORF, Germany, June 5, 2018 /PRNewswire/ -- The STATIN trial (RandomiSed conTrolled trial with prAvasTatin versus placebo for preventIoN of preeclampsia) is a European interventional trial, steered by the Fetal Medicine Foundation (FMF) and the Fundación para la Formación e Investigación Sanitaria (FFIS), to evaluate possible preventive effects of pravastatin in women at high risk of developing late-onset preeclampsia. Preeclampsia, a fatal multisystem disorder that complicates about 2-5% of pregnancies, is a major cause for maternal and fetal morbidity and mortality. Still there is no cure for the disease but delivery of the baby prior to term.
During routine hospital pregnancy visits in Spain, Italy, Belgium, Romania and the UK more than 23,000 pregnant women at 35+0 to 36+6 weeks' gestation will be screened to identify high-risk participants for subsequent development of preeclampsia. During this routine visit maternal characteristics and medical history will be recorded, mean arterial pressure and maternal serum biomarkers, PlGF and sFlt-1, will be measured for a multifactoral assessment of the individual risk for late-onset preeclampsia. The concentrations of the two biomarkers will be measured using Thermo Fisher's serum biomarker assays, B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR.
Screened positive women with a high risk for developing preeclampsia will be invited to participate in the randomised STATIN trial. The trial is registered on ISRCTN (ISRCTN16123934): http://www.isrctn.com/ISRCTN16123934. Please also see: https://fetalmedicine.org/research/new-randomized-trials.
These products are not FDA cleared but CE marked. Availability of these products is related to the registration status in the countries. For more information, please visit: www.thermoscientific.com/brahms.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
Contact Information: Dr. Rita Baxmann
Phone: +49 3302 883 303
E-mail: rita.baxmann@thermofisher.com
